BIOLOGICAL CHARACTERIZATION OF DIUMYCIN, A PHOSPHORUS-CONTAINING GLYCOLIPID ANTIBIOTIC
| Autor: | E. MEYERS, D. SMITH. SLUSARCHYK, F. E. PANSY, H.I. BASCH, W. H. TREJO, P. J. DEBAECKE |
|---|---|
| Rok vydání: | 1972 |
| Předmět: |
Male
medicine.drug_class Staphylococcus Antibiotics Microbial Sensitivity Tests Biology medicine.disease_cause Pneumococcal Infections Microbiology Mice Minimum inhibitory concentration Glycolipid Drug Discovery medicine Animals Pharmacology Streptococcus Phosphorus Staphylococcal Infections Carbenicillin biology.organism_classification Streptomyces Anti-Bacterial Agents Staphylococcus aureus Streptococcus pyogenes Toxicity Glycolipids Neisseria Bacteria Protein Binding medicine.drug |
| Zdroj: | The Journal of Antibiotics. 25:163-170 |
| ISSN: | 1881-1469 0021-8820 |
| DOI: | 10.7164/antibiotics.25.163 |
| Popis: | Diumycin, a phosphorus-containing glycolipid antibiotic, is produced by Streptomyces umbrinus ATCC 15972. It is active against gram-positive bacteria and, to a lesser degree, against gram-negative bacteria. Diumycin affects dividing but not resting cells of Staphylococcus aureus FDA 209 P. The antibiotic is strongly bound by serum. Although primarily bacteriostatic at levels approximating the minimum inhibitory concentration, it is bactericidal at higher levels. Diumycin is active upon subcutaneous administration to mice infected with Streptococcus pyogenes C 203 and Diplococcus pneumoniae and, like other members of the phosphorus-containing glycolipid antibiotic group, demonstrates a unique prophylactic activity against these infections. High and prolonged serum levels (lasting several weeks) were achieved in the plasma of dogs and monkeys after a single, parenteral dose of the antibiotic, and small to moderate amounts of bioactivity were recovered in the urine. Toxicity studies indicate that diumycin is well-tolerated in mice, but may cause a transient liver damage at dose levels near the LD50. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|